Ψ-2C-DFMO

Ψ-2C-DFMO
Clinical data
Other names	ψ-2C-O-35; 4-Difluoromethoxy-2,6-dimethoxyphenethylamine
Routes of; administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None;
Pharmacokinetic data
Duration of action	~18 hours
Identifiers
	IUPAC name 2-[4-(difluoromethoxy)-2,6-dimethoxyphenyl]ethan-1-amine;
Chemical and physical data
Formula	C11H15F2NO3
Molar mass	247.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NCCc1c(OC)cc(cc1OC)OC(F)F;
	InChI InChI=1S/C11H15F2NO3/c1-15-9-5-7(17-11(12)13)6-10(16-2)8(9)3-4-14/h5-6,11H,3-4,14H2,1-2H3; Key:MOGVICJGCUEFKA-UHFFFAOYSA-N;

Ψ-2C-DFMO, also known as ψ-2C-O-35 or as 4-difluoromethoxy-2,6-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and ψ-phenethylamine families.^[2]^[1] It is the phenethylamine (α-demethyl) analogue of ψ-DODFMO and is also structurally related to other psychedelics like difluoromescaline (DFM) and 2C-T-35 (2C-T-DFM).^[2]^[1] The drug has been found to be active at a dose of 17 mg orally, with moderately intense effects and a relatively long duration of around 18 hours.^[2]^[1] Ψ-2C-DFMO was first described in the scientific literature by Daniel Trachsel in 2012.^[2]^[1]

References

^ ^a ^b ^c ^d ^e ^f Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819. The introduction of two fluorine atoms into the 4-MeO group of Ψ-2C-O (61) seems to change biological activity distinctly and leads to a fairly active and long acting compound (Ψ-2C-DFMO, 68. A single experiment with 17 mg was stated to be only moderately intense although a relatively long duration around 18 h was observed. Its α-methyl analog Ψ-DODFMO (69) has been shown to be moderately active in a single experiment with 2x5 mg, which had a long duration of action (around 20 h) as well. [...] Up to now only very little biological data can be found for the derivatives of the 2,4,6-series. Compounds 62–69 may further help understanding the structure-activity relationships of this class. At least two novel derivatives have been assayed. A modification of the human inactive Ψ-2C-O (61, >300 mg) to the 4-difluoromethoxy analog Ψ-2C-DFMO (68, 17 mg) could greatly change the pharmacological properties in humans leading to a fairly potent derivative. The derivative Ψ-DODFMO (69) showed some effects at a dose of 2x5 mg. Although too little data are available so far, this suggests that similarly to the 3,4,5-series, from the presence of an α-methyl group in the 2,4,6-series only a modest difference in human dose may result.
^ ^a ^b ^c ^d Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. p. 885. ISBN 978-3-03788-700-4.

External links

ψ-2C-DFMO - Isomer Design

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

[Trachsel_2012-1] ^ ^a ^b ^c ^d ^e ^f Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819. The introduction of two fluorine atoms into the 4-MeO group of Ψ-2C-O (61) seems to change biological activity distinctly and leads to a fairly active and long acting compound (Ψ-2C-DFMO, 68. A single experiment with 17 mg was stated to be only moderately intense although a relatively long duration around 18 h was observed. Its α-methyl analog Ψ-DODFMO (69) has been shown to be moderately active in a single experiment with 2x5 mg, which had a long duration of action (around 20 h) as well. [...] Up to now only very little biological data can be found for the derivatives of the 2,4,6-series. Compounds 62–69 may further help understanding the structure-activity relationships of this class. At least two novel derivatives have been assayed. A modification of the human inactive Ψ-2C-O (61, >300 mg) to the 4-difluoromethoxy analog Ψ-2C-DFMO (68, 17 mg) could greatly change the pharmacological properties in humans leading to a fairly potent derivative. The derivative Ψ-DODFMO (69) showed some effects at a dose of 2x5 mg. Although too little data are available so far, this suggests that similarly to the 3,4,5-series, from the presence of an α-methyl group in the 2,4,6-series only a modest difference in human dose may result.

[Trachsel_2013-2] Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. p. 885. ISBN 978-3-03788-700-4.

[1]

[2]

See also

References

External links